We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis
Effectiveness and Safety of Glucagon-Like Peptide 1 Drugs for Treating Type 2 Diabetes: A Comparison Study
AI simplified
Abstract
Evidence from 54 studies involving 23,209 patients shows that all GLP-1 receptor agonist regimens except liraglutide 0.3 mg once weekly significantly lowered hemoglobin A1c after 24-30 weeks compared with placebo.
- Dulaglutide 0.75 mg QW, dulaglutide 1.5 mg QW, exenatide 2 mg QW, and several liraglutide regimens demonstrated significant reductions in hemoglobin A1c levels.
- No regimen significantly outperformed dulaglutide 0.75 mg QW, dulaglutide 1.5 mg QW, or various liraglutide doses in lowering hemoglobin A1c.
- The effects of GLP-1RAs on blood pressure, weight, and lipid levels were varied and not consistently significant.
- Safety profiles regarding hypoglycemia and adverse events were comparable among the different GLP-1RA regimens.
AI simplified
Key numbers
23,209
Patients Included
Total number of patients across 54 studies.
9 of 10
Significant Reduction
Regimens significantly lowering after 24-30 weeks.